Barchart.com
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)
32.45 x 2 35.24 x 4
Post-market by (Cboe BZX)
34.85 +0.94 (+2.77%) 04/14/25 [NASDAQ]
32.45 x 2 35.24 x 4
Post-market 35.24 +0.39 (+1.12%) 18:31 ET
News & Headlines for Mon, Apr 14th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Apr 11, 3:01PM CDT

BBIO : 34.85 (+2.77%)
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM GlobeNewswire - Mon Mar 31, 9:00AM CDT

BBIO : 34.85 (+2.77%)
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM GlobeNewswire - Thu Mar 27, 6:00AM CDT

BBIO : 34.85 (+2.77%)
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions GlobeNewswire - Mon Mar 24, 6:30AM CDT

BBIO : 34.85 (+2.77%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Mar 21, 3:00PM CDT

BBIO : 34.85 (+2.77%)
BridgeBio Announces CFO Succession GlobeNewswire - Mon Mar 17, 3:01PM CDT

BBIO : 34.85 (+2.77%)
Prediction: BridgeBio Pharma Will Beat the Market. Here's Why Motley Fool - Mon Mar 3, 6:00PM CST

Explore the exciting world of BridgeBio Pharma (NASDAQ: BBIO) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and...

NVDA : 110.71 (-0.20%)
BBIO : 34.85 (+2.77%)
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt GlobeNewswire - Wed Feb 26, 1:49AM CST

BBIO : 34.85 (+2.77%)
BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt GlobeNewswire - Mon Feb 24, 3:09PM CST

BBIO : 34.85 (+2.77%)
BridgeBio Pharma: Q4 Earnings Snapshot AP - Thu Feb 20, 6:50AM CST

BridgeBio Pharma: Q4 Earnings Snapshot

BBIO : 34.85 (+2.77%)

Barchart Exclusives

These 2 Dividend Aristocrats Are Top Stocks to Buy in Times of Uncertainty Barchart - 10 minutes ago
These companies offer consistent dividend growth and a strong industry presence. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
UTC
Reserve Your Spot